Gain Therapeutics, Inc. Stock price

Equities

GANX

US36269B1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
4.68 USD +4.23% Intraday chart for Gain Therapeutics, Inc. +2.86% +43.34%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 304K Sales 2024 * 700K Capitalization 75.81M
Net income 2023 * -22M Net income 2024 * -22M EV / Sales 2023 * 249 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 108 x
P/E ratio 2023 *
-2.98 x
P/E ratio 2024 *
-3.8 x
Employees 30
Yield 2023 *
-
Yield 2024 *
-
Free-Float 83.8%
More Fundamentals * Assessed data
Dynamic Chart
Gain Therapeutics, Inc. Appoints Gianluca Fuggetta as the Vice President of Finance and Principal Financial Officer from Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, Effective March 1, 2024 CI
Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024 CI
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024. CI
Gain Therapeutics, Inc. Announces Xavi Barril Leaves as Chief Technology Officer CI
HC Wainwright Trims Price Target on Gain Therapeutics to $9 From $10, Keeps Buy Rating MT
Gain Therapeutics, Inc. Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model CI
Gain Therapeutics Closes $10.1 Million Public Offering, Private Placement of Shares, Warrants MT
Top Premarket Decliners MT
Gain Therapeutics Shares Tumble After Announcement of Public Offering MT
Gain Therapeutics, Inc. announced that it expects to receive $5.000176 million in funding CI
Gain Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson?s Disease CI
Maxim Starts Gain Therapeutics at Buy With $10 Price Target MT
Gain Therapeutics Says Data Shows GT-02287 Significantly Decreases Parkinson's Pathology MT
Gain Therapeutics Presents New Preclinical Data Demonstrating A Reduction of Plasma Neurodegeneration Biomarker NfL After Administration of Its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model CI
More news
1 day+4.23%
1 week+2.86%
Current month+4.23%
1 month+18.78%
3 months+112.73%
6 months+39.70%
Current year+43.34%
More quotes
1 week
4.40
Extreme 4.4
4.80
1 month
3.83
Extreme 3.8333
5.33
Current year
3.17
Extreme 3.17
5.33
1 year
2.00
Extreme 2
6.19
3 years
2.00
Extreme 2
17.93
5 years
2.00
Extreme 2
17.93
10 years
2.00
Extreme 2
17.93
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 21-10-18
Director of Finance/CFO 35 22-06-30
Director of Finance/CFO 64 23-04-09
Members of the board TitleAgeSince
Director/Board Member 56 20-12-31
Director/Board Member 63 20-06-30
Chief Executive Officer 59 21-10-18
More insiders
Date Price Change Volume
24-03-01 4.68 +4.23% 103,245
24-02-29 4.49 +0.67% 63,103
24-02-28 4.46 -3.67% 71,139
24-02-27 4.63 +2.89% 104,707
24-02-26 4.5 -1.10% 65,845

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Its drug discovery platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.68 USD
Average target price
8.8 USD
Spread / Average Target
+88.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Gain Therapeutics, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW